Meiji Seika Pharma Explained

Meiji Seika Pharma Co., Ltd.
Trading Name:Meiji
Native Name:Meiji Seika ファルマ株式会社
Native Name Lang:ja
Type:Subsidiary
Foundation:Tokyo, Japan (Tokyo Kashi Company)
Location:4-16, Kyobashi Nitchome, Chuo, Tokyo, Japan
Key People:Hanji Sōma (Founder)
Parent:Meiji Holdings

, formerly is a Japanese pharmaceutical company. It is currently a subsidiary of Meiji Holdings[1] and a Japanese leader in the area of infectious disease with 18% market share. It markets treatments for depression, obsessive-compulsive disorder, vaccines and allergy drugs. Meiji Pharma is doing research in generic anticancer drugs and biosimilars with partner organisations.[2]

It is a confectionery and pharmaceutical company that manufactures a wide range of products including Hello Panda and Yan Yan. Its competitors include Ezaki Glico, Kabaya, Lotte Confectionery and Morinaga.

They acquired the Stauffer Biscuit Company based in York, Pennsylvania, USA in 2004.[3]

On April 1, 2009, Meiji Seika Kaisha, Ltd. and Meiji Dairies Corporation established a joint holding company, Meiji Holdings, which is a constituent of the Nikkei 225 index. Two years later on the day, the food and healthcare business was taken over by Meiji Dairies to form "Meiji Co., Ltd.", and Meiji Seika was reorganized to a pharmaceutical company "Meiji Seika Pharma Co., Ltd." In 2014 Meiji acquired Medreich for $290 million, an Indian company active in selling generic pharmaceuticals to Europe, Asia and Africa.[4]

External links

Notes and References

  1. Web site: Meiji Seika Pharma Co., Ltd. Meiji Holdings Co., Ltd.. 2020-10-01. www.meiji.com. en.
  2. News: Top Global Pharmaceutical Company Report - The Pharma 1000. Torreya . 19 August 2022.
  3. Web site: Stauffer's Original Animal Crackers History. 2020-10-01. www.stauffers.com. 2008-09-08. https://web.archive.org/web/20080908095717/http://www.stauffers.net/company/history. dead.
  4. News: Japan's Meiji Holdings acquires Medreich for Rs 1,720 crore. The Economic Times . 12 June 2014 . 19 August 2022.